Katja I Seitz,Sabine C Herpertz
Katja I Seitz
Globally, nearly 1 billion people are affected by mental disorders. Psychotherapy, despite its demonstrated efficacy, often shows only limited effects. Current estimates suggest that fewer than half of the patients achieve a clinically rele...
Nachruf auf Prof. em. Dr. med. Dr. h.c. mult. Jules Angst : 11.12.1926–15.05.2026 [0.03%]
献给emeritus Prof. Dr. med. Dr. h.c. mult. Jules Angst的讣告：1926年12月11日-2026年5月15日
Martin Preisig,Michael Bauer,Erich Seifritz
Martin Preisig
Editorial
Der Nervenarzt. 2026 Aug 10. DOI:10.1007/s00115-026-02010-0 2026
[Neuromodulation as the fourth pillar in the treatment of depression : A position paper of the German Center for Mental Health] [0.03%]
[神经调控作为治疗抑郁症的第四要素：德国精神卫生中心立场文件]
Sarah Kayser,Beatrix Barth,Malek Bajbouj et al.
Sarah Kayser et al.
Background: Depressive disorders are associated with a high burden of disease; a substantial proportion of patients show insufficient response despite guideline-based pharmacotherapy and psychotherapy, particularly in tre...
[Psychiatric aspects of commercially available products containing cannabidiol] [0.03%]
市售含大麻二酚产品的心理卫生学问题
Maximilian Gahr
Maximilian Gahr
Background: Cannabidiol (CBD) has gained sustained public, medical, and scientific attention in recent years. The prevalence of use of commercially available products containing CBD (CPC) is correspondingly high. ...
[Vitamin D supplementation in depression-Meaningful, evidence-based or guideline-compliant?] [0.03%]
[抑郁症中的维生素D补充-有意义的、基于证据的或符合指南的?]
Astrid Röh,Ramona Hiltensperger,Michael Schepp et al.
Astrid Röh et al.
[Suicidal ideation with instrumental components at inpatient psychiatric admission or discharge: clinical, ethical and judicial implications and recommendations for action] [0.03%]
以自杀念头伴工具性手段为主因的住院或出院的临床、伦理及司法意义及应对建议
D Schwerthöffer,B Schäfer,U Zimmermann
D Schwerthöffer
Background: The treatment of patients who report suicidal ideation if they are not admitted as inpatients or discharged from inpatient treatment, raises clinical, judicial and ethical concerns. ...
[Experienced stigmatization within the somatic healthcare system : A survey of people with diagnoses of severe mental illnesses] [0.03%]
[身心疾病医疗体系中的标签化体验：重性精神疾病患者的调查]
Naomi Jiménez,Michael Strunz,Frank Jacobi
Naomi Jiménez
Background and objective: Individuals with severe mental illness (SMI) suffer from poorer somatic health and increased mortality compared to the general population. As experiences of stigmatization can have a negative imp...
[When AI is involved in making decisions. Ethical considerations on shared decision-making in psychotherapeutic-psychiatric treatment] [0.03%]
[当AI参与决策时。心理治疗-精神病治疗中共享决策的伦理考量]
Eva Kuhn,Laura Fässler,Florian Funer
Eva Kuhn
Background: Artificial intelligence (AI) is on the rise in the treatment of persons with psychiatric disorders. It can integrate diverse data points, analyze patterns and thereby generate clinically relevant insights that...
N Scherbaum,U Bonnet,K Müller-Vahl
N Scherbaum
[Psychotropic drug research in Germany: challenges of early benefit assessment and precision psychiatry] [0.03%]
德国精神药物研究：早期效益评估和精准精神病学面临的挑战
Gerhard Gründer,Holger Bielen,Karl Broich et al.
Gerhard Gründer et al.
Background: The path to more precise and innovative psychotropic drugs is arduous and lengthy due to the complexity of mental illnesses and high regulatory hurdles. Nevertheless, several drugs have been developed and appr...